IL-1ra serum levels in disease stages of MS--a marker for progression?
Standard
IL-1ra serum levels in disease stages of MS--a marker for progression? / Heesen, C; Sieverding, F; Buhmann, Carsten; Gbadamosi, Joystone.
in: ACTA NEUROL SCAND, Jahrgang 101, Nr. 2, 2, 2000, S. 95-97.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - IL-1ra serum levels in disease stages of MS--a marker for progression?
AU - Heesen, C
AU - Sieverding, F
AU - Buhmann, Carsten
AU - Gbadamosi, Joystone
PY - 2000
Y1 - 2000
N2 - Interleukin-1 (IL-1) is one of the major proinflammatory cytokines expressed consistently in multiple sclerosis (MS) lesions. Interleukin-1 receptor antagonist (IL-1ra) is the only known naturally occurring specific antagonistic cytokine counteracting IL-1. Thus IL-1ra may have a downregulating potential in the disease course of MS. We analysed if circulating IL-1ra could be associated with different disease stages of MS in sera of 84 MS patients and 18 controls. IL-1ra showed considerable variations in MS patients and controls. Nevertheless we found significantly elevated serum levels in active as well as in stable disease stages compared to controls. IL-1ra levels were higher in progressive disease courses compared to relapsing-remitting MS, but not statistically significant (median: 516 versus 434 pg/ml). Further analysis with larger groups of patients and longitudinal studies will clarify if IL-1ra is useful as a prognostic serum marker in MS.
AB - Interleukin-1 (IL-1) is one of the major proinflammatory cytokines expressed consistently in multiple sclerosis (MS) lesions. Interleukin-1 receptor antagonist (IL-1ra) is the only known naturally occurring specific antagonistic cytokine counteracting IL-1. Thus IL-1ra may have a downregulating potential in the disease course of MS. We analysed if circulating IL-1ra could be associated with different disease stages of MS in sera of 84 MS patients and 18 controls. IL-1ra showed considerable variations in MS patients and controls. Nevertheless we found significantly elevated serum levels in active as well as in stable disease stages compared to controls. IL-1ra levels were higher in progressive disease courses compared to relapsing-remitting MS, but not statistically significant (median: 516 versus 434 pg/ml). Further analysis with larger groups of patients and longitudinal studies will clarify if IL-1ra is useful as a prognostic serum marker in MS.
M3 - SCORING: Zeitschriftenaufsatz
VL - 101
SP - 95
EP - 97
JO - ACTA NEUROL SCAND
JF - ACTA NEUROL SCAND
SN - 0001-6314
IS - 2
M1 - 2
ER -
